Business Context and Reporting Period
Company: Werewolf Therapeutics, Inc. (HOWL)
Reporting Period: Quarter ended March 31, 2026
Business Overview: An early-stage biopharmaceutical company developing therapeutics (INDUKINE and INDUCER molecules) to stimulate the immune system for cancer treatment. The company has no approved products and has not generated product revenue.
Strategic Status: In February 2026, the company initiated a "2026 Restructuring" and a strategic review process to explore alternatives (e.g., asset sales, mergers) to maximize stockholder value. This included a reduction in force of 64% of the workforce.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.5) million | $(18.1) million |
| Operating Expenses | $13.3 million | $18.0 million |
| Cash and Cash Equivalents (End of Period) | $46.5 million | $92.0 million |
| Net Cash Used in Operating Activities | $(10.6) million | $(18.9) million |
| Total Debt (Note Payable, net) | $28.8 million | $28.2 million |
| Accumulated Deficit | $(488.9) million | $(432.7) million |
Material Changes vs. Prior Period
- Reduced Burn Rate: Net loss decreased by $4.6 million (25%) and operating expenses decreased by $4.7 million (26%) compared to Q1 2025. This was driven by a 64% workforce reduction and significant curtailment of R&D spending.
- R&D Expenses: Decreased from $13.1 million to $8.2 million. The decline was primarily due to reduced personnel costs, lower clinical trial costs as trials approach completion, and reduced manufacturing and lab consumable costs.
- Cash Position: Cash and cash equivalents declined by approximately $10.6 million during the quarter, compared to a decline of $18.9 million in the prior year quarter.
- Derivative Liability: Recognized a gain of $0.7 million related to the change in fair value of the derivative liability associated with the K2HV Loan Agreement.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has stated there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the date of the report. The company expects cash resources to be insufficient to fund operations beyond the near term without additional financing or successful strategic transactions.
Subsequent Events (Post-March 31, 2026)
- Asset Sale: On May 6, 2026, the company sold its "898 Program" (JZP898) to Jazz Pharmaceuticals for an upfront payment of $21.0 million, with an additional $2.0 million contingent on license assignment.
- Debt Repayment: On May 6, 2026, the company repaid all obligations under its K2HV Loan Agreement (approx. $31.4 million), extinguishing the debt.
- Lease Termination: On May 7, 2026, the company agreed to terminate its Watertown, MA lease effective October 31, 2026, for a termination fee of $2.7 million.
Risks
- Capital Requirements: The company requires substantial additional funding to continue operations and development. Failure to raise capital could force a cessation of operations.
- Strategic Review Uncertainty: There is no assurance that the strategic review process will result in a transaction that enhances stockholder value.
- Nasdaq Compliance: The company received a deficiency letter regarding the minimum bid price requirement ($1.00) and has until August 3, 2026, to regain compliance to avoid delisting.
Investor Verification Checklist
- Cash Runway: Verify the updated cash runway following the $21M asset sale and $31.4M debt repayment to assess immediate liquidity stability.
- Strategic Alternatives: Monitor the outcome of the strategic review process (Piper Sandler engagement) for potential M&A or partnership announcements.
- Nasdaq Status: Track the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before August 3, 2026.
- Restructuring Costs: Confirm the total final cost of the 2026 Restructuring (estimated at $6.4M total) and any additional impairment charges related to the asset sale.
- Debt Extinguishment: Review the accounting treatment of the debt extinguishment and any associated gains or losses in the subsequent filing.